MedPath

University of Central Florida

University of Central Florida logo
🇺🇸United States
Ownership
Private
Established
1963-06-10
Employees
10K
Market Cap
-
Website
http://www.ucf.edu

Gastrointestinal Cancer Symposium 2025: Key Advances in Treatment Strategies

• Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer. • Encorafenib combined with cetuximab and chemotherapy shows significant improvement in overall response rate for BRAF V600E-mutated metastatic colorectal cancer. • TACE plus camrelizumab and rivoceranib extends progression-free survival in patients with unresectable hepatocellular carcinoma, offering a manageable safety profile.

FDA Panel Supports Condoliase Injection for Herniated Disc-Related Leg Pain

• FDA advisory panel voted 8-4 in favor of condoliase for radicular leg pain due to lumbar disc herniation, highlighting its potential for patients who have not responded to conservative treatments. • The panel emphasized the need for a narrow indication, focusing on patients with confirmed nerve root impingement and failure of at least 6 weeks of conservative therapy. • Concerns were raised regarding potential immune-related adverse events and long-term effects on spinal health, necessitating careful monitoring and further research. • Condoliase, currently available in Japan, works by reducing disc volume and relieving pressure on the nerve root, offering a non-opioid alternative to surgery for some patients.

Brooks Rehabilitation and Universities Partner to Advance Motor Speech Disorder Treatment

• Brooks Rehabilitation partners with UCF, JU, and UF to launch the Eric Sorensen Motor Speech Program (ESMSP) for adults with motor speech disorders. • The ESMSP aims to improve access to specialized services through clinician training and evidence-based resources, addressing a critical unmet need. • The Sorensen Integrated Motor Speech (SIMS) program, developed by university partners, certifies Brooks SLPs in advanced motor speech disorder treatment. • Phase II of the ESMSP will focus on studying acquired motor speech disorders through traditional and intensive service models to enhance patient outcomes.
© Copyright 2025. All Rights Reserved by MedPath